Stay updated with breaking news from Arcus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the...
Wedbush reiterated their outperform rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has a $30.00 target price on the stock. Wedbush also issued estimates for Arcus Biosciences’ FY2028 earnings at $1.87 EPS. A number of other research analysts […]
Wedbush reiterated their outperform rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a research note released on Thursday, MarketBeat reports. Wedbush currently has a $30.00 price objective on the stock. Wedbush also issued estimates for Arcus Biosciences’ FY2028 earnings at $1.87 EPS. Other equities analysts have also recently issued research reports about […]
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical...
HAYWARD, Calif.--(BUSINESS WIRE)--Feb 21, 2024--